An EGFR Co-Amplified and De Novo Long Noncoding RNA HELDR Promotes Glioblastoma Malignancy through KAT7-Driven Gene...

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Epidermal growth factor receptor (EGFR) amplification in extrachromosomal DNAs (ecDNAs) is common in glioblastoma (GBM).
• Directly targeting EGFR has yielded limited success in GBM treatment.
• The role of co-amplified non-coding RNAs in GBM pathogenesis remains largely unexplored.

Purpose of the Study:

• To identify and characterize novel non-coding RNAs co-amplified with EGFR in GBM.
• To elucidate the functional role of the identified lncRNA in GBM tumorigenesis.
• To explore therapeutic strategies targeting this lncRNA in combination with EGFR-targeted therapies.

Main Methods:

• Characterization of a novel glioblastoma-specific long non-coding RNA (lncRNA), HELDR, co-amplified with EGFR in ecDNAs.
• Investigated HELDR's mechanism of action, including its interaction with p300 and its effect on KAT7 transcription.
• Assessed the therapeutic potential of targeting HELDR or KAT7 in preclinical GBM models.

Main Results:

• Identified HELDR, a lncRNA promoting GBM tumorigenicity independently of EGFR signaling.
• Demonstrated that HELDR recruits p300 to the KAT7 promoter, leading to increased H3K27 acetylation and KAT7 transcription.
• Showed that KAT7 activation drives GBM malignancy through specific histone modifications (H3K14ac, H4K12ac).
• Found that targeting HELDR or KAT7 significantly improves the efficacy of anti-EGFR treatments in GBM.

Conclusions:

• HELDR is a key driver in EGFR-amplified GBM, functioning through the KAT7 pathway.
• Targeting HELDR or KAT7 represents a promising therapeutic strategy to overcome resistance to EGFR-targeted therapies in GBM.
• This study highlights the importance of investigating lncRNAs co-amplified with oncogenes in cancer treatment strategies.